(Reuters) - BOSTON, July 24 - Biogen Idec Inc reported better-than-expected earnings on Tuesday, boosted by strong sales of its drugs for multiple sclerosis and cancer, and raised its outlook for the year.
The Cambridge, Massachusetts-based biotechnology company posted a profit of 70 cents a share excluding one-time items, compared to 57 cents a year ago.
Read more at Reuters.com Market News
The Cambridge, Massachusetts-based biotechnology company posted a profit of 70 cents a share excluding one-time items, compared to 57 cents a year ago.
Read more at Reuters.com Market News
No comments:
Post a Comment